

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Bortezomib and thalidomide for the first-line treatment of multiple myeloma

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

<b>Version of matrix of consultees and commentators reviewed:</b>					
Provisional matrix of consultees and commentators sent for consultation					
<b>Summary of comments, action taken, and justification of action:</b>					
	<i>Proposal:</i>	<i>Proposal made by:</i>		<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
1.	<i>Please note that Schering-Plough is not listed on the matrix currently. This company currently makes second-line medications for the treatment of multiple myeloma and as such has an interest in this therapy area</i>	<i>Schering-Plough</i>		<i>Noted</i>	

2.	<i>Transplant Support Network to be removed as a stakeholder</i>	<i>NICE secretariat</i>		<i>Removed</i>	<i>The Transplant Support Network does not meet the inclusion criteria and has therefore been removed from the matrix</i>
3.	<i>UK Transplant to be removed as a stakeholder</i>	<i>NICE secretariat</i>		<i>Removed</i>	<i>UK Transplant is part of NHS Blood and Transplant service. NHS Blood and Transplant service is listed on the matrix therefore UK Transplant has been removed from the matrix.</i>